Argos Therapeutics Inc

Argos Therapeutics — Technical Presentation (April 2017)

35 slides from Argos Therapeutics's technical presentation, Apr 18, 2017

  1. Slide 1: Results of February Interim Analysis of ADAPT Trial and Perspective on Decision to Keep Trial Open

    Webcast April 18, 2017 Results of February Interim Analysis of ADAPT Trial and Perspective on Decision to Keep Trial Open

  2. Slide 2: Forward-looking statements

    Any statements in this presentation about Argos' future expectations, plans and prospects, including statements about the ADAPT trial and the interim data from the trial, Argos' anticipated meeting with the FDA, clinical development of Argos' product candidates and future expectations and plans and

  3. Slide 3: Webcast Overview

    □ Interim data summary » Phase 3 ADAPT trial design and IDMC recommendation » P rimary and secondary outcomes in the intent - to - treat (ITT) population □ Rationale for continuing ADAPT and longer term survival follow - up » High degree of censored data and tail - of - curve effect with immunothera

  4. Slide 4: Phase 3 ADAPT Trial Design and Interim Data Summary

    Phase 3 ADAPT Trial Design and Interim Data Summary 4

  5. Slide 5: Phase 3 ADAPT Trial Design

    5 Phase 3 ADAPT Trial Design • Randomized, open label study in patients with newly diagnosed (first line) metastatic renal cell carcinoma (clear cell histology) conducted under a Special Protocol Assessment • Stratification by measureable disease and by Heng risk factors ( 77 % Intermediate Risk and

  6. Slide 6: IDMC Recommendation

    Planned Analyses % Targeted # of Events (Deaths) Number of Events Interim Analysis 1 25% 72 Interim Analysis 2 50% 145 Interim Analysis 3 75% 217 Final Analysis 100% 290 □ IDMC charter established in 2012 based on assumptions regarding survival and standard statistical methodology at that time 6 □ I

  7. Slide 7: Patient Disposition at Interim Analysis

    Total Subjects Randomized n =462 Combination Arm n=307 Control Arm n=155 Combo Subjects Who Died n=149 Combo Subjects Alive n=158 Control Subjects Who Died n=69 Control Subjects Alive n=86 Patient Disposition at Interim Analysis 1 □ ITT population (all randomized patients) includes 39 patients who n

  8. Slide 8: ITT Population Characteristics

    □ No significant differences in baseline characteristics between the combination arm and the control arm □ Median follow - up is 20 months (range: 0.4 – 47.7 months) □ Median number of doses of Rocapuldencel - T is 8 □ Generally comparable subsequent standard - of - care treatments in each arm 8 ITT

  9. Slide 9: Primary Endpoint Interim Analysis - Overall Survival

    Interim Analysis Combination Arm Control Arm ITT Population n=307 n=155 Percentage Censored Subjects 51% 55% Median Overall Survival (months) 1 27.7 32.4 95% Confidence Interval (CI) 23.0, 35.9 22.5, - Hazard Ratio ( 95% CI) - Unadjusted 1.10, (0.83, 1.46) Hazard Ratio (95% CI) – Adjusted * 1.06, (0

  10. Slide 10: Key Secondary Endpoint Interim Analyses

    Progression Free Survival Combination Arm Control Arm ITT Population n=307 n=155 Median Progression Free Survival (months) 6.0 7.8 95% CI 5.8, 6.7 5.9, 9.3 Hazard Ratio 1.15 95% CI 0.92, 1.44 10 Objective Response Rate Combination Arm Control Arm ITT Population n=307 n=155 Best Overall Response, n (

  11. Slide 11: Rationale For Continuing ADAPT and Longer-Term Survival Follow-up

    Rationale For Continuing ADAPT and Longer - Term S urvival Follow - up 11

  12. Slide 12: Rationale For Continuing ADAPT And Longer Term Survival Follow-up

    □ Potential for delayed treatment effect (tail - of - curve) with immunotherapy » Interim analyses may not fully capture the potential benefit of an active immunotherapy due to insufficient long - term follow - up 1 » Rocapuldencel - T induces long - term memory immune responses » > 50% subjects cen

  13. Slide 13: Duration of Follow-up at February Interim Analysis by Tertile of Randomization

    FEB 2013 – JUN 2014 Duration of Follow - up at February Interim Analysis by Tertile of Randomization Tertile 2 Middle Cohort (n=154) (56% censored) Tertile 1 Earliest Cohort (n=154) (44% Censored) JUN 2014 – JAN 2015 JAN 2015 – OCT 2015 Tertile 3 Latest Cohort (n=154) (58% Censored) Months

  14. Slide 14: Overall Survival by Time of Randomization

    14 Combination Arm Control Arm Delta Hazard Ratio N % Censored Median OS (Months) N % Censored Median OS (Months) M onths 1 st 33 % randomized 102 46 30.1 (23.3, - ) 52 40 22.2 (17.2, - ) +7.9 0.88 (0.56, 1.36) 1 st 66 % randomized 205 51 30.4 (24.8, - ) 103 50 32.4 (21.7, - ) - 2.0 0.98 (0.70, 1.37

  15. Slide 15: Kaplan-Meier Analysis of Overall Survival in Tertile 1

    Combination Arm (n=102) m OS = 30.1 mo Standard - of - Care Treatment Arm (n=52) m OS = 22.2 mo Hazard Ratio 0.876 Kaplan - Meier Analysis of Overall Survival in Tertile 1 15

  16. Slide 16: Immune Response Interim Analysis

    Immune Response Interim Analysis 16

  17. Slide 17: Immune Responder Criteria and Median Overall Survival

    Combination Arm n=109 (1) Subjects Meeting Immune Responder Criteria (2) Median Overall Survival (months) 3 95% Confidence Interval At Anytime 96/109 88% Not Reached 30.1, - After 3 Doses 76/106 72% 36.3 28.3, - After 5 Doses 71/99 72% 36.3 28.2, - After 7 Doses 58/72 81% Not Reached - , - 17 (1) Of

  18. Slide 18: Correlation Between Increase in Memory T Cells and Overall Survival

    18 Patient Group N Spearman’s Correlation Coefficient * P - value Patients who received at least 3 Doses 106 0.21 0.030 Patients who received at least 5 Doses 99 0.06 0.544 Patients who received at least 7 Doses 72 0.38 0.001 * Pre - specified analysis assessed using post - dose change from baseline

  19. Slide 19: Number of Memory T Cells at Baseline not Associated with Survival

    Number of Memory T Cells* at Baseline not Associated with Survival 19 <Median: N=57 (67% censored) ≥Median: N=58 (60% censored) Top one - third: N=38 (58% censored) Survival Post hoc analysis includes 115 patients who had baseline memory T cell measurements out of the 117 subjects analyzed for immun

  20. Slide 20: Greater Increase in Memory T Cells above Baseline Associated with Improved Survival

    Greater Increase in Memory T Cells* above Baseline after 7 Doses Associated with Improved Survival 20 <Median: N=41 (73% censored) ≥Median: N=42 (81% censored) Top one - third: N=27 (93% censored) Post hoc analysis includes 83 patients who received at least 7 doses out of the 117 patients analyzed f

  21. Slide 21: Antigen-Specific Memory T Cells Increase only after AGS-003 Administration

    Antigen - Specific Memory T Cells Increase only after AGS - 003 Administration 14

  22. Slide 22: Summary and Perspective on Continuing ADAPT

    □ IDMC recommended discontinuation of ADAPT for futility » Based on 3rd Interim Analysis: 75% of 290 targeted events ( death) as of Feb 3, 2017 » Assessment that study unlikely to demonstrate statistically significant improvement in o verall survival in intent - to - treat population based on pre -

  23. Slide 23: Appendix

    Appendix | —

  24. Slide 24: ITT Population: Baseline Characteristics

    Combination Arm Control Arm Treatment Group Comparability p - value* ITT Population n=307 n=155 Median Age 60.0 yr 61.0 yr 0.615 Gender, Male 227 73.9% 114 73.5% >0.999 Race 0.114 White 288 93.8% 151 97.4% Non - White 19 6.2% 4 2.6% Time from Initial Dx 2.67 mo 2.63 mo Metastatic Disease 0.866 Yes 3

  25. Slide 25: ITT Population: Rocapuldencel-T Dosing

    Combination Arm n=307 AGS - 003 Doses Received Number of Subjects Cumulative Subjects AGS - 003 Doses Received Number of Subjects Cumulative Subjects 0 39 307 10 33 100 1 5 268 11 14 67 2 4 263 12 10 53 3 9 259 13 15 43 4 9 250 14 11 28 5 23 241 15 8 17 6 30 218 16 5 9 7 35 188 17 3 4 8 26 153 18 1

  26. Slide 26: ITT Population: Subsequent Standard-of-Care Treatment Exposure

    Combination Arm n=307 Control Arm n=155 Number or Subsequent Standard - of - Care Treatments 194 63.2% 87 56.1% 0 113 36.8% 68 43.9% 1 87 28.3% 40 25.8% 2 47 15.3% 26 16.8% 3 29 9.4% 11 7.1% 4 21 6.8% 6 3.9% 5 7 2.3% 1 0.6% 6 1 0.3% 2 1.3% 7 2 0.7% 0 0.0% 8 0 0.0% 1 0.6% □ Number of subsequent stand

  27. Slide 27: ITT Population: Subsequent Standard-of-Care Treatment Exposure

    Combination Arm n=307 Control Arm n=155 Subsequent Standard - of - Care Treatment Treatment Phase Follow - up Phase Entire Study Treatment Phase Follow - up Phase Entire Study Axitinib 52 44 91 29.6% 13 29 38 24.5% Nivolumab 19 76 89 29.0% 3 26 27 17.4% Everolimus 38 29 65 21.2% 12 22 31 20.0% Pazop

  28. Slide 28: ITT Population: Kaplan-Meier Analysis of Overall Survival

    28 AGS - 003 Combination Treatment Arm ( n=307) Standard - of - Care Treatment Arm ( n=155) ITT Population: Kaplan - Meier Analysis of Overall Survival

  29. Slide 29: ITT Population: Subgroup Analyses of Overall Survival

    Combination Arm Control Arm Intermediate Risk Population* N=235 N=120 Median Overall Survival (months) 30.1 32.5 95% CI 24.0, - 25.2, - Hazard Ratio 1.11 95% CI 0.80, 1.56 Poor Risk Population* N=72 N=35 Median Overall Survival (months) 18.7 21.1 95% CI 12.0, - 10.2, - Hazard Ratio 1.03 95% CI 0.60,

  30. Slide 30: Subgroup Analyses of Overall Survival by Individual Heng Risk Factors

    Combination Arm (n=307) Control Arm (n=155) Hazard Ratio Number of Risk Factors Median OS (months) Median OS (months) 1 n=84 30.4 n=43 Not Reached 1.36 2 n=151 28.2 n=77 32.4 1.01 3 n=52 21.2 n=26 Not Reached 1.21 4 n=20 11.9 n=9 16.6 0.8 30 ITT Population: Subgroup Analyses of Overall Survival by I

  31. Slide 31: ITT Population: Subgroup Analyses of Overall Survival

    Combination Arm (n=307) Control Arm (n=155) Hazard Ratio Subsequent Therapy Median OS (months) Median OS (months) Yes n=194 27.2 n=87 23.0 0.89 No n=113 Not Reached n=68 Not Reached 1.50 Number of Subsequent Therapies 0 n=113 Not Reached n=68 Not Reached 1.50 1 n=87 18.7 n=40 17.2 0.96 2 n=47 35.5 n

  32. Slide 32: Summary of Adverse Events - Safety Population

    Combination Arm Control Arm Subjects Who Received Any Amount of Study Medication (n=299) n, % (n=141) n, % Pre - Treatment Period Any Adverse Events 10 (3.3%) 2 (1.4%) Any Serious Adverse Events 1 (0.3%) 0 (0.0%) Any Grade 3/4/5 AEs 1 (0.3%) 0 (0.0%) Randomized Treatment Period Any Adverse Events 29

  33. Slide 33: Summary of Adverse Events - Safety Population

    Combination Arm Control Arm Subjects Who Received Any Amount of Study Medication (n=299) n, % (n=141) n, % Randomized Treatment Period (Continued) Any Serious Adverse Events 129 (43.1%) 47 (33.3%) AGS - 003 Related SAEs 0 (0.0%) - Standard of Care Related SAEs 48 (16.1%) 24 (17.0%) Discontinuation o

  34. Slide 34: Baseline Characteristics by Tertile

    First Tertile Feb 2013 – June 2014 First 66% Feb 2013 – Jan 2015 Total Subjects - 100% FEB 2013 – Oct 2015 Combination Arm Control Arm Combination Arm Control Arm Combination Arm Control Arm Tertile Population n=102 n=52 n=205 n=103 n=307 n=155 Median Age , yr 59.0 59.0 59.0 61.0 60.0 61.0 Gender, M

  35. Slide 35: Pre-planned Immune Responder Analysis Baseline Characteristics

    Combination Arm Immune Responder Subgroup n=289 n=96 Median Age 60.0 yr 58.5 yr Gender, Male 212 73.4% 64 66.7% Race White 271 93.8% 92 95.8% Non - White 18 6.2% 4 4.2% Metastatic Disease Yes 287 99.3% 95 99.0% Measurable 256 88.6% 79 82.3% Non - measurable 31 10.7% 16 16.7% No 2 0.7% 1 1.0% Heng Ri

Argos Therapeutics — Technical Presentation (April 2017) on 6ix